Company / R&D per Share
Amylyx Pharmaceuticals, Inc. R&D per Share History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.82
FY2025
5-year range
$0.82 / $13.31
FY2021-FY2025
Trend
-45.8%
vs FY2024
Sector context
#152 of 208
Health Care
What the data says
At $0.82, Amylyx Pharmaceuticals, Inc.'s r&d per share ranks #152 of 208 in the Health Care sector. R&D per Share has declined for 3 consecutive years, from $13.31 in FY2022 to $0.82 in FY2025.
Based on SEC 10-K filings.
0.82 in FY2025 with a 3-year CAGR of -60.5%.
Declined from $1.89 to $0.82 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -60.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#152 of 208 in Health CareTop 73% of 208This company $0.82 Sector average $28.82
▼
-97.1% below sector average
Key checks
Key Insights
- Amylyx Pharmaceuticals, Inc.'s r&d per share has declined for 3 consecutive years.
- In FY2025, r&d per share decreased 45.8% year-over-year.
- Ranks #152 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2022.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.82 | -45.8% |
| FY2024 | $1.52 | -19.9% |
| FY2023 | $1.89 | -85.8% |
| FY2022 | $13.31 | +99.1% |
| FY2021 | $6.69 | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026